PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
NCT ID: NCT00454779
Last Updated: 2018-10-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
113 participants
INTERVENTIONAL
2007-01-01
2014-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
NCT00256295
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
NCT01844817
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
NCT00100789
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
NCT01087970
Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
NCT00017498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Panitumumab + Docetaxel + Cisplatin
Panitumumab
experimental arm
Cisplatin
experimental arm
Docetaxel
experimental arm
Arm 2
control
Cisplatin
chemotherapy arm
Docetaxel
chemotherapy arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin
chemotherapy arm
Panitumumab
experimental arm
Docetaxel
chemotherapy arm
Cisplatin
experimental arm
Docetaxel
experimental arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease by CT scan
* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
* Age: 18 years or older
* Adequate hematologic, renal, metabolic, hepatic \& thyroid function
Exclusion Criteria
* CNS metastases, or nasopharyngeal carcinoma
* History of interstitial lung disease
* History of another primary cancer
* Any co-morbid disease that would increase risk of toxicity
* Active infection requiring systemic treatment
* Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tucson, Arizona, United States
Research Site
Jonesboro, Arkansas, United States
Research Site
Duarte, California, United States
Research Site
La Jolla, California, United States
Research Site
La Verne, California, United States
Research Site
Los Angeles, California, United States
Research Site
Santa Cruz, California, United States
Research Site
Aurora, Colorado, United States
Research Site
Denver, Colorado, United States
Research Site
Norwich, Connecticut, United States
Research Site
Newark, Delaware, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Lakeland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
New Port Richey, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Athens, Georgia, United States
Research Site
Griffin, Georgia, United States
Research Site
Marietta, Georgia, United States
Research Site
Centralia, Illinois, United States
Research Site
Elk Grove Village, Illinois, United States
Research Site
Evanston, Illinois, United States
Research Site
Park Ridge, Illinois, United States
Research Site
Zion, Illinois, United States
Research Site
Wichita, Kansas, United States
Research Site
Ashland, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Paducah, Kentucky, United States
Research Site
Baltimore, Maryland, United States
Research Site
Baltimore, Maryland, United States
Research Site
Frederick, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Lansing, Michigan, United States
Research Site
Pascagoula, Mississippi, United States
Research Site
Columbia, Missouri, United States
Research Site
Jefferson City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Billings, Montana, United States
Research Site
Omaha, Nebraska, United States
Research Site
Henderson, Nevada, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Binghamton, New York, United States
Research Site
Mineola, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Nyack, New York, United States
Research Site
Rochester, New York, United States
Research Site
Syracuse, New York, United States
Research Site
The Bronx, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Canton, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Langhorne, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Scranton, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Charleston, South Carolina, United States
Research Site
Greenville, South Carolina, United States
Research Site
Memphis, Tennessee, United States
Research Site
Arlington, Texas, United States
Research Site
Corpus Christi, Texas, United States
Research Site
Corpus Christi, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Galveston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Abingdon, Virginia, United States
Research Site
Chesapeake, Virginia, United States
Research Site
Morgantown, West Virginia, United States
Research Site
Madison, Wisconsin, United States
Research Site
Marshfield, Wisconsin, United States
Research Site
Graz, , Austria
Research Site
Leoben, , Austria
Research Site
Linz, , Austria
Research Site
Vienna, , Austria
Research Site
Brasschaat, , Belgium
Research Site
Bruges, , Belgium
Research Site
Kortrijk, , Belgium
Research Site
Libramont, , Belgium
Research Site
Liège, , Belgium
Research Site
Ottignies, , Belgium
Research Site
Wilrijk, , Belgium
Research Site
Brno, , Czechia
Research Site
Prague, , Czechia
Research Site
Znojmo, , Czechia
Research Site
Angers, , France
Research Site
Lens, , France
Research Site
Perpignan, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Kaunas, , Lithuania
Research Site
Vilnius, , Lithuania
Research Site
San Juan, , Puerto Rico
Research Site
Banská Bystrica, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Nové Zámky, , Slovakia
Research Site
Prešov, , Slovakia
Research Site
Spišská Nová Ves, , Slovakia
Research Site
Santander, Cantabria, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Girona, Catalonia, Spain
Research Site
L'Hospitalet de Llobregat, Catalonia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wirth LJ. PARTNER: a study of panitumumab plus chemotherapy for first-line treatment of advanced head and neck cancer. Commun Oncol. 2008;5(Supp 14):1-4.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20050236
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.